PARP1 and cancer: Hence, PARP1 inhibitors have achieved major clinical successes in the treatment of cancers with defects in the Homologous Recombination DNA repair pathway associated with BRCA1 and BRCA2 mutations or when combined with traditional DNA damaging agents such as chemotherapy and/or radiotherapy [29].